All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Understanding biomarkers and patient eligibility for CAR T cell therapies in diffuse large B cell lymphoma.

Jul 24, 2023
Learning objective: After reading this article, learners will be able to cite developments in CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Bookmark this article

Here, we share a presentation by Kieron Dunleavy, GW Cancer Center, Washington D.C., US, on biomarkers and patient eligibility for chimeric antigen receptor T-cell (CAR T-cell) therapies in diffuse large B cell lymphoma (DLBCL).

In this presentation, Dunleavy discusses key clinical trials and subtypes of DLBCL that are associated with mutations which may represent therapeutic biomarkers (Figure 1), as well as key factors that impact CAR T-cell therapy response, specifically in high grade B-cell lymphoma (Figure 2).

Figure 1. Molecular biology of DLBCL and their candidate drug targets* 

*Adapted from Level, et al.1


Figure 2. Impact of high-grade B-cell lymphoma on efficacy of CAR T-cells* 

*Adapted from Ali A, et al.2 Created with 

Watch or download the presentation to learn more about CAR T-cell therapy in patients with DLBCL, including:

  • The currently approved therapies and clinical trials associated with these CAR T-cell therapies
  • Key factors that impact CAR T-cell therapy response
  • The subtypes of DLBCL and their World Health Organization (WHO) and International Consensus Criteria 2022 classifications
  • The impact of disease characteristics on the outcome of treatment assessed in ZUMA-7 (NCT03391466) compared with TRANSFORM (NCT03575351).

Key points

  • Disease characteristics, tumor biological characteristics, tumor microenvironment and interval response have been shown to impact CAR T-cell response.
  • The ZUMA-7 and TRANSFORM clinical trials showed that CAR T-cell therapy was more advantageous compared with autologous stem cell transplant.
  • There are several genetic subtypes of DLBCL with hallmark genetic features that can set the stage for candidate drug targeting.
  • Older patients (≥65 years old), patients with activated B-cell cases, or high grade B-cell lymphomas had particularly good survival outcomes compared to other disease characteristics.3,4
  • High grade B-cell lymphoma has been shown to have better survival outcomes post CAR T-cell therapy compared with other DLBCL subtypes, both in clinical trials and real-world evidence studies.1

Session slides

To download the slides presented, click here.

Download here

This activity was supported through an educational grant from Bristol Myers Squibb.

  1. Ali A, Goy A, Dunleavy K, et al. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. 2022;140(13):1461-1469. DOI: 10.1182/blood.2022016226
  2. Level LD, Alizadeh AA, Bergsagel PF, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140(21):2193-2227. DOI: 1182/blood.2022015854
  3. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. 2022;386(7):640-654. DOI: 10.1056/NEJMoa2116133
  4. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. 2022;399(10343):2294-2308. DOI: 10.1016/S0140-6736(22)00662-6

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox